|
|
Article: Actiq(TM) Clinical Trials Demonstrate Efficacy for Breakthrough Pain; Data Presented at the ASCO Annual Meeting
- Article from:
- PR Newswire
- Article date:
- May 20, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SALT LAKE CITY, May 20 /PRNewswire/ -- Results from pivotal studies of Actiq(TM) (oral transmucosal fenranyl citrate), a new product being developed to control breakthrough pain in patients with cancer, were presented May 19 - 20 by clinical investigators at the annual meeting of the American Society of Clinical Oncology (ASCO) in Denver, CO. Severe flares of breakthrough pain affect more than 50% of cancer pain patients and are often difficult to treat. These study results are a subset of the Actiq New Drug Application (NDA) currently under review by the Food and Drug Administration (FDA), submitted by Anesta Corp. (Nasdaq: NSTA) in November 1996.
In ...